Dimerix Limited · ASX:DXB
Dimerix — Shareholder Meeting (November 2019)
17 slides from Dimerix's shareholder meeting presentation, Nov 28, 2019
Slide 1: Company Review
Company Review Dr Nina Webster CEO & Managing Director @ Dimerix
Slide 2: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different fro
Slide 3: FY2019 and FY2020 milestones
For personal use only FY 2019 Executive Management New DMX-200 patent European Orphan Drug First patient dosed First patient dosed Innovation Connections Grant Team restructure granted in US Designation for DMX- Diabetic Kidney FSGS Phase 2a study awarded for working on Aug18 Aug18 200 in FSGS Disea
Slide 4: Cash Reserves
For personal use only Cash Reserves at June 2019 $3.56 million FY2019 net operating cash expenditure $2.7m 4
Slide 5: Share price performance
For personal use only Share price performance 5
Slide 6: For personal use only
For personal use only • Clinical readout for both studies in Q2 2020 • In clinic within 2 years Potential for more new pipeline candidates 6
Slide 7: A pipeline of drugs identified using Receptor-HIT
A pipeline of drugs identified using Receptor-HIT Programs based on the critical scientific rationale that GPCRs act as a complex with other GPCRs and have novel pharmacology when in complex Strategic Fit Dimerix is developing a commercial pipeline of drugs for G Protein-Coupled Receptors (GPCR) lar
Slide 8: Product candidates in the pipeline, with clinical read outs expected in 2020
For personal use only 3 product candidates in the pipeline, with 2 clinical read outs expected in 2020 Pivotal Study Preclinical Phase 1 Phase 2 Market Compound Disease Target Focal Segmental Glomerulosclerosis Phase 2 readout mid-2020 DMX-200 (FSGS) Phase 2 readout mid-2020 DMX-200 Diabetic Kidney
Slide 9: For personal use only
For personal use only
Slide 10: For personal use only
For personal use only • • • • • 10
Slide 11: For personal use only
505(b)(1) regulatory pathway for New Chemical For personal use only Entity (NCE) planned IND submission planned in 2020, Proposed non- post Phase 2 data clinical and read-out specifications for drug manufacture confirmed as Pre-IND meeting appropriate for NDA held in November 2019 for FSGS Phase 3 p
Slide 12: For personal use only
For personal use only
Slide 13: COPD market
Asia Pacific expected to be For personal use only fastest growing Global Initiatives COPD market at CAGR ~8.7% Global COPD • World Health Organization (WHO) treatment market No candidates in • COPD Foundation US$14 billion (2017) late stage & projected to • American Thoracic Society development incr
Slide 14: For personal use only
For personal use only • • • • • 14
Slide 15: For personal use only
For personal use only
Slide 16: FY2020 milestones and goals
For personal use only FY 2020 FSGS Phase 2a study 1st DMX-200 patents Diabetic Kidney Complete GMP DMX-700 added to fully recruited announced in Europe Disease Phase 2 study commercial batch pipeline Jul19 Jul19 fully recruited manufacture Oct19 Sep19 Oct19 Ongoing partnering Diabetic Kidney FSGS De
Slide 17: End of Presentation
DIMERIX End of Presentation @ Dimerix